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Background 
Rituximab (RTX) is an anti-CD20 antibody used successfully in ANCA-associated vasculitis 
(AAV) for induction and maintenance of remission. 
Objective 
To evaluate the long term efficacy and safety of chronic pre-emptive RTX therapy in AAV. 
Methods 
Retrospective study of 38 AAV patients treated with RTX between April 2004 and September 
2011 for active disease. Cumulative CYC dose prior to RTX was 14 (0-250) grams. RTX was 
initiated as two 1-gram infusions 2 weeks apart and thereafter 2gr RTX was re-administered 
annually to achieve long-term B cell depletion. Patients were closely monitored during 46.5 
(2-88) months follow up with clinical and serological surveillance (Ig levels, lymphocyte 
subsets). Values given indicate median and range. 
Results 
A total of 38 AAV patients were treated with RTX after 58.5 months (1-270) disease 
duration; 58% had renal and 63% had lung involvement. Median RTX dose was 8 (2-13) 
grams during 5 (1-10) infusion rounds. All patients had a clinical response, but eleven 
relapses were recorded (flare rate of 7.4 /100 patient years). At last follow up all patients were 
off immunosuppressive (IS) drugs aside from 4 transplanted patients and 1 psoriatic patient. 
Daily prednisolone dose at last follow-up was 5 mg (0-30). 
Fourteen patients (37%) discontinued RTX: 6 patients for hypogammaglobulinemia, 3 for 
severe infections, 2 for transplantation, 2 for malignancy, 2 for late-onset neutropenia, 1 for 
colitis, 1 for inefficacy and 1 for pregnancy.  
Severe infections necessitating hospitalization and intravenous treatment occurred in 9 
patients (26%). Risk factors for severe infections were renal involvement (p=0.003), higher 
cumulative CYC dose (OR=1.04, p=0.027) and higher prednisolone dose at last visit 
(OR=1.18, p=0.05.). On the other hand, patients with orbital and subglottic involvements had 
decreased risk for severe infections (p=0.025). Neither the cumulative dose nor the number of 
rounds of RTX was associated with severe infections.  
Lower ratio CD4/CD8 prior RTX (OR=0.22, p=0.066) and at last visit (OR=0.28, p=0.052) 
increased the risk for severe infections. The decrease in total immunoglobulin during RTX 
therapy (OR=1.34, p=0.056) increased the risk for severe infections. 
Conclusions 
Chronic preemptive RTX treatment aimed to deplete peripheral B cells is effective and leads 
to relapse rates lower than with standard therapy in AAV patients. Chronic preemptive RTX 
therapy also allows discontinuation of IS drugs in most patients and significantly reduces 
steroid use. However, 37% of AAV patients discontinued RTX due to side effects. The risk 
for severe infections was increased with renal involvement, cumulative CYC dose, 
prednisolone dose, T cells defect and decrease in total immunoglobulin during RTX therapy. 
 
 
 
 
